Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01777334 · ClinicalTrials.gov registry record · Phase 3
The Purpose of This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotriopium 18 mcg Once Daily Over a 24-week Treatment Period in Subjects With COPD
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 905
- Enrollment target
NCT01777334 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 905 participants.
The verdict
NCT01777334, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 905 participants
- Enrollment target
Study Summary
The purpose of this 24 week study is to evaluate the spirometric lung function effect (trough FEV1) of Umeclidinium/Vilanterol 62.5/25 once daily compared to Tiotropium 18 mcg once daily along with safety assessments in subjects with COPD.
Interventions
- DRUG Tiotropium 18 mcg
- DRUG Umeclidinium/Vilanterol 62.5/25 mcg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 905 participants |
| Start Date | 2013-01-23 |
| Est. Completion | 2013-09-24 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01777334
The ClinicalTrials.gov registry entry for NCT01777334 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 905 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Tiotropium 18 mcg is the first listed.
NCT01777334 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01777334 about?
NCT01777334 is a clinical study titled "The Purpose of This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotriopium 18 mcg Once Daily Over a 24-week Treatment Period in Subjects With COPD". The purpose of this 24 week study is to evaluate the spirometric lung function effect (trough FEV1) of Umeclidinium/Vilanterol 62.5/25 once daily compared to Tiotropium 18 mcg once daily along with safety assessments in subjects with COPD.
What is the current status of trial NCT01777334?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 905 participants. The study started on 2013-01-23. Estimated completion is 2013-09-24.
What interventions are being tested in trial NCT01777334?
The interventions under investigation include: Tiotropium 18 mcg (DRUG), Umeclidinium/Vilanterol 62.5/25 mcg (DRUG).
Who is sponsoring clinical trial NCT01777334?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.